Avantor, Inc. AVTR
We take great care to ensure that the data presented and summarized in this overview for Avantor, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVTR
View all-
Vanguard Group Inc Valley Forge, PA64.5MShares$1.61 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA63.7MShares$1.59 Billion1.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD51.1MShares$1.28 Billion0.8% of portfolio
-
Black Rock Inc. New York, NY42.8MShares$1.07 Billion0.03% of portfolio
-
Boston Partners Boston, MA28.6MShares$714 Million0.9% of portfolio
-
Barrow Hanley Mewhinney & Strauss LLC Dallas, TX23.6MShares$589 Million2.15% of portfolio
-
Canada Pension Plan Investment Board Toronto Ontario, A621.5MShares$536 Million0.59% of portfolio
-
Janus Henderson Group PLC London, X014.3MShares$356 Million0.2% of portfolio
-
New Mountain Vantage Advisers, L.L.C. New York, NY14MShares$350 Million10.05% of portfolio
-
State Street Corp Boston, MA14MShares$349 Million0.02% of portfolio
Latest Institutional Activity in AVTR
Top Purchases
Top Sells
About AVTR
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Insider Transactions at AVTR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2024
|
Mala Murthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+23.82%
|
-
|
|
May 09
2024
|
Lan Kang Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+21.91%
|
-
|
|
May 09
2024
|
John Carethers Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+22.77%
|
-
|
|
May 09
2024
|
Juan Andres Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+14.91%
|
-
|
|
May 09
2024
|
Michael Severino Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+16.32%
|
-
|
|
May 09
2024
|
Jonathan M Peacock Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+4.17%
|
-
|
|
May 09
2024
|
Gregory L Summe Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+17.13%
|
-
|
|
May 09
2024
|
Joseph R Massaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,477
+23.94%
|
-
|
|
Apr 16
2024
|
Randy Lee Stone EVP, Laboratory Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
6,762
-9.03%
|
$162,288
$24.6 P/Share
|
|
Apr 05
2024
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
569
-0.68%
|
$14,225
$25.87 P/Share
|
|
Mar 08
2024
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,685
-9.67%
|
$92,125
$25.63 P/Share
|
|
Feb 29
2024
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Open market or private sale
|
Direct |
4,910
-4.85%
|
$117,840
$24.52 P/Share
|
|
Feb 29
2024
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
13,074
-13.48%
|
$313,776
$24.53 P/Share
|
|
Feb 27
2024
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Open market or private sale
|
Direct |
6,203
-5.78%
|
$148,872
$24.49 P/Share
|
|
Feb 25
2024
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-0.53%
|
$11,208
$24.35 P/Share
|
|
Feb 25
2024
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
511
-0.59%
|
$12,264
$24.35 P/Share
|
|
Feb 25
2024
|
Brittany Hankamer EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
369
-1.53%
|
$8,856
$24.35 P/Share
|
|
Feb 25
2024
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,685
-0.69%
|
$184,440
$24.35 P/Share
|
|
Feb 25
2024
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
505
-1.88%
|
$12,120
$24.35 P/Share
|
|
Feb 24
2024
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
648
-0.73%
|
$15,552
$24.35 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 507K shares |
|---|---|
| Bona fide gift | 40K shares |
| Payment of exercise price or tax liability | 308K shares |
|---|---|
| Bona fide gift | 40K shares |
| Open market or private sale | 60.4K shares |